Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women

Bone ◽  
2009 ◽  
Vol 44 ◽  
pp. S236-S237
Author(s):  
K. Thompson ◽  
F. Keech ◽  
D. McLernon ◽  
K. Vinod ◽  
D. Tosh ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Acute Phase ◽  
Acute Phase Response ◽  
Phase Response ◽  
Menopausal Women ◽  
Post Menopausal

Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women

Bone ◽  
2011 ◽  
Vol 49 (1) ◽  
pp. 140-145 ◽  
Author(s):  
Keith Thompson ◽  
Fran Keech ◽  
David J. McLernon ◽  
Kumar Vinod ◽  
Robin J. May ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Acute Phase ◽  
Acute Phase Response ◽  
Phase Response ◽  
Menopausal Women ◽  
Post Menopausal

Characterization of and Risk Factors for the Acute-Phase Response After Zoledronic Acid

2011 ◽  
Vol 66 (2) ◽  
pp. 97-99 ◽  
Author(s):  
I. R. Reid ◽  
G. D. Gamble ◽  
P. Mesenbrink ◽  
P. Lakatos ◽  
D. M. Black
Keyword(s):  
Risk Factors ◽  
Zoledronic Acid ◽  
Acute Phase ◽  
Acute Phase Response ◽  
Phase Response

Acute phase response and zoledronic acid therapy

2013 ◽  
Author(s):  
Svetlana Yureneva ◽  
Oksana Yakushevskaya ◽  
Vera Smetnik ◽  
Gennady Sukchich
Keyword(s):  
Zoledronic Acid ◽  
Acute Phase ◽  
Acute Phase Response ◽  
Phase Response ◽  
Acid Therapy

Acute Phase Response After Zoledronic Acid is Associated with Long-Term Effects on White Blood Cells

2013 ◽  
Vol 93 (3) ◽  
pp. 249-252 ◽  
Author(s):  
Maurizio Rossini ◽  
Silvano Adami ◽  
Ombretta Viapiana ◽  
Gaia Tripi ◽  
Roberta Zanotti ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Acute Phase ◽  
Blood Cells ◽  
Acute Phase Response ◽  
White Blood Cells ◽  
Phase Response ◽  
Long Term Effects

Cytokines and Insulin Resistance after Zoledronic Acid-Induced Acute Phase Response

2014 ◽  
Vol 43 (6) ◽  
pp. 544-555 ◽  
Author(s):  
Georgia Kassi ◽  
Konstantinos Papamichael ◽  
Garyfallia Papaioannou ◽  
Irene Giagourta ◽  
Stavroula Thanou ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Zoledronic Acid ◽  
Acute Phase ◽  
Acute Phase Response ◽  
Phase Response

scholarly journals Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid

2010 ◽  
Vol 95 (9) ◽  
pp. 4380-4387 ◽  
Author(s):  
I. R. Reid ◽  
G. D. Gamble ◽  
P. Mesenbrink ◽  
P. Lakatos ◽  
D. M. Black
Keyword(s):  
Risk Factors ◽  
Zoledronic Acid ◽  
Adverse Events ◽  
Acute Phase ◽  
Acute Phase Response ◽  
Drug Users ◽  
Acid Group ◽  
Antiinflammatory Drug ◽  
Nonsteroidal Antiinflammatory Drug ◽  
Phase Response

Context: Intravenous aminobisphosphonates often cause an acute-phase response (APR), but the precise components of this, its frequency, and the risk factors for its development have not been systematically studied. Objective: The objective of the study was to characterize the APR and determine its frequency and the risk factors for its development. Design: The study was an analysis of adverse events from a large randomized trial. Setting: This was a multicenter international trial. Patients: Patients included 7765 postmenopausal women with osteoporosis. Intervention: Zoledronic acid 5 mg annually or placebo was the intervention. Main Outcome Measure: Adverse events occurring within 3 d of zoledronic acid infusion were measured. Results: More than 30 adverse events were significantly more common in the zoledronic acid group and were regarded collectively as constituting an APR. These were clustered into five groups: fever; musculoskeletal (pain and joint swelling); gastrointestinal (abdominal pain, vomiting, diarrhea); eye inflammation; and general (including fatigue, nasopharyngitis, edema). A total of 42.4% of the zoledronic acid group had an APR after the first infusion, compared with 11.7% of the placebo group. All APR components had their peak onset within 1 d, the median duration of the APR was 3 d, and severity was rated as mild or moderate in 90%. Stepwise regression showed that APR was more common in non-Japanese Asians, younger subjects, and nonsteroidal antiinflammatory drug users and was less common in smokers, patients with diabetes, previous users of oral bisphosphonates, and Latin Americans (P < 0.05 for all). Conclusion: This analysis identifies new components of the APR and provides the first assessment of risk factors for it. Despite its frequency, APR rarely resulted in treatment discontinuation in this study.

scholarly journals Characteristics Associated with Acute-Phase Response following First Zoledronic Acid Infusion in Brazilian Population with Osteoporosis

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Bruno S. A. Ferreira ◽  
Bernardo M. da Cunha ◽  
Luciana P. Valadares ◽  
Larissa A. Moreira ◽  
Frederico G. A. Batista ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Acute Phase ◽  
Acute Phase Response ◽  
Laboratory Data ◽  
Phase Response ◽  
Symptom Duration ◽  
Acid Infusion ◽  
Hydroxyvitamin D ◽  
Oral Bisphosphonate ◽  
Before And After

We aimed to evaluate characteristics associated with acute-phase response (APR) following first zoledronic acid infusion in a Brazilian cohort. This retrospective cohort study enrolled all adults with osteoporosis who underwent a first zoledronic acid infusion at our centre between June 2015 and June 2019. Clinical demographics (age, sex, diabetes, smoking, body mass index, and previous oral bisphosphonate use) and laboratory data (calcium, parathyroid hormone, renal function, and serum 25-hydroxyvitamin D and carboxy-terminal crosslinked telopeptide of type 1 collagen [CTX], both before and after infusion) were compared between patients with and without APR. We evaluated association magnitude between the presence of APR and clinical variables through logistic regression. This study enrolled 400 patients (women, 80%). APR was observed in 24.5% (n = 98) of patients. The mean symptom duration in days was 3.5 ± 2.8. Patients with APR were younger (67 ± 12 vs. 71 ± 11 years; p = 0.001 ), used oral bisphosphonates less frequently (34% × 50%; p = 0.005 ), and had greater baseline CTX (0.535 ng/mL [0.375, 0.697] × 0.430 [0.249, 0.681]; p = 0.03 ) and ΔCTX (−69 [−76; −50] × −54 [−72; −23]; p = 0.002 ) than those without APR. The other variables were similar between the groups. Only ΔCTX was associated (OR, 0.62; 95% CI 0.41–0.98) with APR after accounting for age and bisphosphonate use. APR occurred in 24.5% of the cohort. Younger age and absence of prior oral bisphosphonate use were associated with APR following first zoledronic acid infusion. APR was associated with ΔCTX (but no other variables) after adjusting for these factors.

Severe acute phase response after intravenous zoledronic acid in adult patients with cerebral palsy

2016 ◽  
Vol 46 (4) ◽  
pp. 506-507 ◽  
Author(s):  
A. Trinh ◽  
P. Wong ◽  
P. R. Ebeling ◽  
P. J. Fuller ◽  
F. Milat
Keyword(s):  
Cerebral Palsy ◽  
Zoledronic Acid ◽  
Acute Phase ◽  
Acute Phase Response ◽  
Phase Response ◽  
Adult Patients

Acute phase response and mineral status following low dose intravenous zoledronic acid in children

Bone ◽  
2007 ◽  
Vol 41 (3) ◽  
pp. 366-370 ◽  
Author(s):  
Craig F. Munns ◽  
Mansoor H. Rajab ◽  
Janet Hong ◽  
Julie Briody ◽  
Wolfgang Högler ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Acute Phase ◽  
Acute Phase Response ◽  
Low Dose ◽  
Phase Response ◽  
Mineral Status
Sign in / Sign up

Export Citation Format

Share Document